Details of the SBP

General Information of Synthetic Binding Protein (SBP) (ID: SBP000138)
SBP Name
BiTE Pacanalotamab
Synonyms
AMG-420; AMG 420; BI 836909
Design Method Traditional methods (Site-directed mutagenesis and/or Directed evolution)
Highest Status Phase I
Protein Scaffold Information of This SBP
Scaffold ID PS018
Scaffold Info
[1] , [2]
Scaffold Name BiTE
Scaffold Class Antibody fragment
Fold Type Beta-Sheets + Loops
Binding Target(s) of This SBP (BTS)
BTS Name Details Mechanism Application Affinity Research Organization Ref
Tumor necrosis factor receptor superfamily member 17
BTS Info
Binder Multiple myeloma [ICD-11: 2A83.Y] N.A. Amgen; Boehringer Ingelheim [1] , [2]
T-cell surface glycoprotein CD3
BTS Info
Binder Multiple myeloma [ICD-11: 2A83.Y] N.A. Amgen; Boehringer Ingelheim [1] , [2]
Clinical Trial Information of This SBP
NCT02514239 Click to show the Detail
Indication Relapsed or Refractory Multiple Myeloma
Phase Phase I
Title An Open Label, Phase I, Dose Escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous Doses of BI 836909 in Relapsed and/or Refractory Multiple Myeloma Patients
Status Completed
Sponsor Boehringer Ingelheim
NCT03836053 Click to show the Detail
Indication Relapsed or Refractory Multiple Myeloma
Phase Phase I
Title A Phase Ib Multicenter, Open-label, Expansion Study to Assess the Safety and Efficacy of AMG 420 as Monotherapy in Subjects With Relapsed and/or Refractory Multiple Myeloma
Status Active, not recruiting
Sponsor Amgen
References
1 The BiTE (bispecific T-cell engager) platform: Development and future potential of a targeted immuno-oncology therapy across tumor types. Cancer. 2020 Jul 15;126(14):3192-3201.
2 B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia. 2020 Apr;34(4):985-1005.